Nolvadex Pediatric Exclusivity Extension Would Block Generics Until 2003
AstraZeneca expects to receive a pediatric exclusivity extension for the breast cancer agentNolvadex (tamoxifen) based on studies in McCune-Albright syndrome
AstraZeneca expects to receive a pediatric exclusivity extension for the breast cancer agentNolvadex (tamoxifen) based on studies in McCune-Albright syndrome